• 中国精品科技期刊
  • 《中文核心期刊要目总览》收录期刊
  • RCCSE 中国核心期刊(5/114,A+)
  • Scopus收录期刊
  • 美国《化学文摘》(CA)收录期刊
  • WHO 西太平洋地区医学索引(WPRIM)收录期刊
  • 《中国科学引文数据库(CSCD)》核心库期刊 (C)
  • 中国科技核心期刊
  • 中国科技论文统计源期刊
  • 《日本科学技术振兴机构数据库(中国)》(JSTChina)收录期刊
  • 美国《乌利希期刊指南》(UIrichsweb)收录期刊
  • 中华预防医学会系列杂志优秀期刊(2019年)

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

2019年中国肿瘤流行病学研究进展

陈宏达 郑荣寿 王乐 吕章艳 杜灵彬 魏文强 代敏

陈宏达, 郑荣寿, 王乐, 吕章艳, 杜灵彬, 魏文强, 代敏. 2019年中国肿瘤流行病学研究进展[J]. 中华疾病控制杂志, 2020, 24(4): 373-379. doi: 10.16462/j.cnki.zhjbkz.2020.04.001
引用本文: 陈宏达, 郑荣寿, 王乐, 吕章艳, 杜灵彬, 魏文强, 代敏. 2019年中国肿瘤流行病学研究进展[J]. 中华疾病控制杂志, 2020, 24(4): 373-379. doi: 10.16462/j.cnki.zhjbkz.2020.04.001
CHEN Hong-da, ZHENG Rong-shou, WANG Le, LU: Zhang-yan, DU Ling-bin, WEI Wen-qiang, DAI Min. Progress in cancer epidemiology research in China in 2019[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2020, 24(4): 373-379. doi: 10.16462/j.cnki.zhjbkz.2020.04.001
Citation: CHEN Hong-da, ZHENG Rong-shou, WANG Le, LU: Zhang-yan, DU Ling-bin, WEI Wen-qiang, DAI Min. Progress in cancer epidemiology research in China in 2019[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2020, 24(4): 373-379. doi: 10.16462/j.cnki.zhjbkz.2020.04.001

2019年中国肿瘤流行病学研究进展

doi: 10.16462/j.cnki.zhjbkz.2020.04.001
基金项目: 国家重点研发计划精准医学专项(2017YFC0907900;2016YFC0901400);中国医学科学院医学与健康科技创新工程(2017-I2M-1-006);国家自然科学基金(81703309);北京市科技新星计划(Z191100001119065)
详细信息
    通讯作者:

    代敏, E-mail:daimin2002@hotmail.com

  • 中图分类号: R730.1

Progress in cancer epidemiology research in China in 2019

Funds: National Key Research and Development Project-Precision Medicine(2017YFC0907900, 2016YFC0901400); CAMS Innovation Fund for Medical Science(2017-I2M-1-006); National Natural Science Foundation of China(81703309); Beijing Nova Program of Science and Technology(Z191100001119065)
More Information
  • 摘要: 恶性肿瘤已成为中国居民的主要死因之一。近些年来, 中国政府积极推进肿瘤预防和控制领域的研究工作, 取得了很大的进步。本文简要汇总中国在肿瘤流行病学领域的研究进展, 具体包括2019年的肿瘤负担、癌症危险因素及其干预、筛查和早期发现、癌症防治专项行动(2019-2022年)方案等方面, 以期为我国肿瘤防治工作的有效开展提供技术支撑和理论依据。
  • [1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
    [2] 孙可欣, 郑荣寿, 张思维, 等. 2015年中国分地区恶性肿瘤发病和死亡分析[J].中国肿瘤, 2019, 28(1): 1-11. DOI:10.11735/j.issn.1004-0242.2019.01.

    A001. Sun KX, Zheng RS, Zhang SW, et al. Report of cancer incidence and mortality in different areas of China, 2015[J]. China Cancer, 2019, 28(1): 1-11. DOI: 10.11735/j.issn.1004-0242.2019.01.A001.
    [3] 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志, 2019, 41(1): 19-28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.005.

    Zheng RS, Sun KX, Zhang SW, et al. Report of cancer epidemiology in China, 2015[J]. Chin J Oncol, 2019, 41(1): 19-28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.005.
    [4] Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J]. Lancet Glob Health, 2018, 6(5): e555-e567. DOI: 10.1016/S2214-109X(18)30127-X.
    [5] Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14(CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075. DOI: 10.1016/S0140-6736(17)33326-3.
    [6] Chen Z, Chen J, Collins R, et al. China Kadoorie biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up[J]. Int J Epidemiol, 2011, 40(6): 1652-1666. DOI: 10.1093/ije/dyr120.
    [7] Song C, Lv J, Liu Y, et al. Associations between hepatitis B virus infection and risk of all cancer types[J]. JAMA Netw Open, 2019, 2(6): e195718. DOI: 10.1001/jamanetworkopen.2019.5718.
    [8] Si J, Yu C, Guo Y, et al. Chronic hepatitis B virus infection and total and cause-specific mortality: a prospective cohort study of 0.5 million people[J]. BMJ Open, 2019, 9(4): e027696. DOI: 10.1136/bmjopen-2018-027696.
    [9] Wang L, Jin G, Yu C, et al. Cancer incidence in relation to body fatness among 0.5 million men and women: findings from the China Kadoorie biobank[J]. Int J Cancer, 2020, 146(4): 987-998. DOI: 10.1002/ijc.32394.
    [10] Li X, Yu C, Guo Y, et al. Association between tea consumption and risk of cancer: a prospective cohort study of 0.5 million Chinese adults[J]. Eur J Epidemiol, 2019, 34(8): 753-763. DOI: 10.1007/s10654-019-00530-5.
    [11] 杨淞淳, 申泽薇, 余灿清, 等.中国成年人排便频率与结直肠癌发病风险的前瞻性关联分析[J].中华流行病学杂志, 2019, 40(4): 382-388. DOI: 10.3760/cma.j.issn.0254-6450.2019.04.003.

    Yang SC, Shen ZW, Yu CQ, et al. Association between the frequency of bowel movements and the risk of colorectal cancer in Chinese adults[J]. Chin J Epidemiol, 2019, 40(4): 382-388. DOI: 10.3760/cma.j.issn.0254-6450.2019.04.003.
    [12] Feng X, Wang G, Lyu Z, et al. The association between fasting blood glucose trajectory and cancer risk in Chinese population without diabetes[J]. Int J Cancer, 2020: epub of ahead. DOI: 10.1002/ijc.32858.
    [13] Lyu Z, Li N, Wang G, et al. Independent and joint associations of blood lipids and lipoproteins with lung cancer risk in Chinese males: A prospective cohort study[J]. Int J Cancer, 2019, 144(12): 2972-2984. DOI: 10.1002/ijc.32051.
    [14] 王刚, 李霓, 冯小双, 等.炎性因子与乳腺癌发病风险的前瞻性队列研究[J].中华疾病控制杂志, 2019, 23(5): 517-521. DOI: 10.16462/j.cnki.zhjbkz.2019.05.005.

    Wang G, Li N, Feng XS, et al. The relationship between inflammatory factors and the risk of breast cancer in Kailuan cohort[J]. Chin J Dis Control Prev, 2019, 23(5): 517-521. DOI: 10.16462/j.cnki.zhjbkz.2019.05.005.
    [15] 王刚, 魏锣沛, 李霓, 等.炎性因子水平与肺癌发病风险的前瞻性队列研究[J].中华肿瘤杂志, 2019, 41(8): 633-637. DOI: 10.3760/cma.j.issn.02533766.2019.08.014.

    Wang G, Wei L, Li N, et al. The relationship between inflammatory markers and the risk of lung cancer: a prospective cohort study[J]. Chin J Oncol, 2019, 41(8): 633-637. DOI: 10.3760/cma.j.issn.02533766.2019.08.014.
    [16] Li X, Chen H, Wang G, et al. Metabolic syndrome components and the risk of colorectal cancer: a population-based prospective study in Chinese men[J]. Front Oncol, 2019, 9: 1047. DOI: 10.3389/fonc.2019.01047.
    [17] Chen R, Ma S, Guan C, et al. The national cohort of esophageal cancer-prospective cohort study of esophageal cancer and precancerous lesions based on high-risk population in China(NCEC-HRP): study protocol[J]. BMJ Open, 2019, 9(4): e027360. DOI: 10.1136/bmjopen-2018-027360.
    [18] 丁克峰.结直肠癌专病队列研究[J].中国科技成果, 2017, 18(24): 14. DOI: 10.3772/j.issn.1009-5659.2017.24.006.

    Ding KF. National cohort study of colorectal cancer[J]. Chinese Journal of Science and Technology Achievements, 2017, 18(24): 14. DOI: 10.3772/j.issn.1009-5659.2017.24.006.
    [19] Chen W, Xia C, Zheng R, et al. Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment[J]. Lancet Glob Health, 2019, 7(2): e257-e269. DOI: 10.1016/s2214-109x(18)30488-1.
    [20] Xia C, Hu S, Xu X, et al. Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study[J]. Lancet Public Health, 2019, 4(9): e462-e472. DOI: 10.1016/s2468-2667(19)30162-8.
    [21] Dai J, Lv J, Zhu M, et al. Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations[J]. Lancet Respir Med, 2019, 7(10): 881-891. DOI: 10.1016/s2213-2600(19)30144-4.
    [22] Lin GW, Xu C, Chen K, et al. Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations[J]. Lancet Oncol, 2020, 21(2): 306-316. DOI: 10.1016/s1470-2045(19)30799-5.
    [23] Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(11): 690-704. DOI: 10.1038/s41575-019-0209-8.
    [24] Parida S, Sharma D. The microbiome-estrogen connection and breast cancer risk[J]. Cells, 2019, 8(12): E1642. DOI: 10.3390/cells8121642.
    [25] Fan X, Alekseyenko AV, Wu J, et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study[J]. Gut, 2018, 67(1): 120-127. DOI: 10.1136/gutjnl-2016-312580.
    [26] Wang Q, Rao Y, Guo X, et al. Oral microbiome in patients with oesophageal squamous cell carcinoma[J]. Sci Rep, 2019, 9(1): 19055. DOI: 10.1038/s41598-019-55667-w.
    [27] Li WQ, Zhang JY, Ma JL, et al. Effects of helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial[J]. BMJ, 2019, 366: l5016. DOI: 10.1136/bmj.l5016.
    [28] Wang SM, Abnet CC, Qiao YL. What have we learned from Linxian esophageal cancer etiological studies?[J]. Thorac Cancer, 2019, 10(5): 1036-1042. DOI: 10.1111/1759-7714.13058.
    [29] Qiao YL, Wu T, Li RC, et al. Efficacy, safety, and immunogenicity of an escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial[J]. J Natl Cancer Inst, 2020, 112(2): 145-153. DOI: 10.1093/jnci/djz074.
    [30] Wilson JM, Jungner YG. Principles and practice of mass screening for disease[J]. Bol Oficina Sanit Panam, 1968, 65(4): 281-393. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=5fb9cdf828d49ce0643ea2faea20900a
    [31] Goffin JR, Flanagan WM, Miller AB, et al. Cost-effectiveness of lung cancer screening in Canada[J]. JAMA Oncol, 2015, 1(6): 807-813. DOI: 10.1001/jamaoncol.2015.2472.
    [32] Lew JB, St John DJB, Xu XM, et al. Long-term evaluation of benefits, harms, and cost-effectiveness of the national bowel cancer screening program in Australia: a modelling study[J]. Lancet Public Health, 2017, 2(7): e331-e340. DOI: 10.1016/S2468-2667(17)30105-6.
    [33] Mandelblatt JS, Lawrence WF, Gaffikin L, et al. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries[J]. J Natl Cancer Inst, 2002, 94(19): 1469-1483. DOI: 10.1093/jnci/94.19.1469.
    [34] Pharoah PD, Sewell B, Fitzsimmons D, et al. Cost effectiveness of the NHS breast screening programme: life table model[J]. BMJ, 2013, 346: f2618. DOI: 10.1136/bmj.f2618.
    [35] de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume ct screening in a randomized trial[J]. N Engl J Med, 2020, 382(6): 503-513. DOI: 10.1056/NEJMoa1911793.
    [36] Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies[J]. BMJ, 2014, 348: g2467. DOI: 10.1136/bmj.g2467.
    [37] Kronborg O, Jorgensen OD, Fenger C, et al. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds[J]. Scand J Gastroenterol, 2004, 39(9): 846-851. DOI: 10.1080/00365520410003182.
    [38] Lindholm E, Brevinge H, Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer[J]. Br J Surg, 2008, 95(8): 1029-1036. DOI: 10.1002/bjs.6136.
    [39] Scholefield JH, Moss SM, Mangham CM, et al. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up[J]. Gut, 2012, 61(7): 1036-1040. DOI: 10.1136/gutjnl-2011-300774.
    [40] Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer[J]. N Engl J Med, 2013, 369(12): 1106-1114. DOI: 10.1056/NEJMoa1300720.
    [41] Nelson HD, Fu R, Cantor A, et al. Effectiveness of breast cancer screening: systematic review and Meta-analysis to update the 2009 U. S. preventive services task force recommendation[J]. Ann Intern Med, 2016, 164(4): 244-255. DOI: 10.7326/M15-0969.
    [42] Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India[J]. N Engl J Med, 2009, 360(14): 1385-1394. DOI: 10.1056/NEJMoa0808516.
    [43] Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early-and late-stage human malignancies[J]. Sci Transl Med, 2014, 6(224): 224ra224. DOI: 10.1126/scitranslmed.3007094.
    [44] Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer[J]. Gut, 2014, 63(2): 317-325. DOI: 10.1136/gutjnl-2012-304149.
    [45] Choi KS, Kwak MS, Lee HY, et al. Screening for gastric cancer in Korea: population-based preferences for endoscopy versus upper gastrointestinal series[J]. Cancer Epidemiol Biomarkers Prev, 2009, 18(5): 1390-1398. DOI: 10.1158/1055-9965.EPI-08-0940.
    [46] Hamashima C. Cancer screening guidelines and policy making: 15 years of experience in cancer screening guideline development in Japan[J]. Jpn J Clin Oncol, 2018, 48(3): 278-286. DOI: 10.1093/jjco/hyx190.
    [47] National Lung Screening Trial Research T, Church TR, Black WC, et al. Results of initial low-dose computed tomographic screening for lung cancer[J]. N Engl J Med, 2013, 368(21): 1980-1991. DOI: 10.1056/NEJMoa1209120.
    [48] Vale DB, Anttila A, Ponti A, et al. Invitation strategies and coverage in the population-based cancer screening programmes in the European Union[J]. Eur J Cancer Prev, 2019, 28(2): 131-140. DOI: 10.1097/CEJ.0000000000000426.
    [49] Parkin CJ, Bell SW, Mirbagheri N. Colorectal cancer screening in Australia: An update[J]. Aust J Gen Pract, 2018, 47(12): 859-863. DOI: 10.31128/AJGP-01-18-4472.
    [50] Zhou Q. MS16.02 NELCIN B3 screening program in China[J]. Journal of Thoracic Oncology, 2018, 13(10, Supplement): S272-S273. DOI: 10.1016/j.jtho.2018.08.154.
    [51] 代敏, 石菊芳, 李霓.中国城市癌症早诊早治项目设计及预期目标[J].中华预防医学杂志, 2013, 47(2): 179-182. DOI: 10.3760/cma.j.issn.0253-9624.2013.02.018.
    [52] 陈万青, 曹毛毛.加强癌症早诊早治, 实施健康中国战略[J].中国肿瘤, 2019, 28(9): 643. DOI:10.11735/j.issn.1004-0242.2019.09.

    A001 Chen WQ, Cao MM. Strengthening cancer early diagnosis and treatment, implementing the strategy of healthy China[J]. China Cancer, 2019, 28(9): 643. DOI: 10.11735/j.issn.1004-0242.2019.09.A001.
    [53] "两癌"筛查[J].中国卫生, 2019, (10): 54.

    Screening for breast cancer and cervical cancer[J]. Chinese Health, 2019, (10): 54.
    [54] Xiao HF, Yan SP, Chen YF, et al. Community-based upper gastrointestinal cancer screening in a randomized controlled trial: baseline results in a non-high-incidence area[J]. Cancer Prev Res(Phila), 2020, 13(3): 317-328. DOI: 10.1158/1940-6207.capr-19-0422.
    [55] Chen W, Zeng H, Chen R, et al. Evaluating efficacy of screening for upper gastrointestinal cancer in China: a study protocol for a randomized controlled trial[J]. Chin J Cancer Res, 2017, 29(4): 294-302. DOI: 10.21147/j.issn.1000-9604.2017.04.02.
    [56] Chen H, Li N, Ren J, et al. Participation and yield of a population-based colorectal cancer screening programme in China[J]. Gut, 2019, 68(8): 1450-1457. DOI: 10.1136/gutjnl-2018-317124.
    [57] He Z, Liu Z, Liu M, et al. Efficacy of endoscopic screening for esophageal cancer in China(ESECC): design and preliminary results of a population-based randomised controlled trial[J]. Gut, 2019, 68(2): 198-206. DOI: 10.1136/gutjnl-2017-315520.
    [58] Chen H, Li N, Shi J, et al. Comparative evaluation of novel screening strategies for colorectal cancer screening in China(TARGET-C): a study protocol for a multicentre randomised controlled trial[J]. BMJ Open, 2019, 9(4): e025935. DOI: 10.1136/bmjopen-2018-025935.
    [59] 中华人民共和国国务院.健康中国行动(2019—2030年)[EB/OL]. (2019-7-15)[2020-3-02]. http://www.gov.cn/xinwen/2019-07/15/content_5409694.htm.

    StateCouncilofthePeople'sRepublicofChina.HealthyChinaaction(2019-2030)[EB/OL].(2019-07-15)[2020-03-02]. http://www.gov.cn/xinwen/2019-07/15/content_5409694.htm.
    [60] 中华人民共和国国家卫生健康委员会.关于印发健康中国行动——癌症防治实施方案(2019-2022年)的通知[EB/OL]. (2019-09-23)[2020-03-02]. http://www.nhc.gov.cn/jkj/s5878/201909/2cb5dfb5d4f84f8881897e232b376b60.shtml.

    NationalHealthCommissionofthePeople'sRepublicofChina.NoticeonprintinganddistributinghealthChinaaction-cancerpreventionandcontrolimplementationplan(2019-2022)[EB/OL].(2019-9-23)[2020-3-02]. http://www.nhc.gov.cn/jkj/s5878/201909/2cb5dfb5d4f84f8881897e232b376b60.shtml.
  • 加载中
计量
  • 文章访问数:  743
  • HTML全文浏览量:  117
  • PDF下载量:  214
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-03-19
  • 修回日期:  2020-04-01
  • 刊出日期:  2020-04-10

目录

    /

    返回文章
    返回